期刊文献+

c-erbB-2、PTEN在乳腺癌中的表达及其意义 被引量:1

The expression and significance of c-erbB-2 and PTEN in breast cancer
下载PDF
导出
摘要 目的 :探讨 c- erb B- 2和 PTEN表达与乳腺癌临床病理参数和预后关系。方法 :对 6 0例行根治或改良根治术的乳腺癌患者进行随访分析 ,石蜡标本行免疫组化 S- P法检测 c- erb B- 2和 PTEN蛋白的表达。结果 :(1) c- erb B- 2阳性表达主要在细胞膜 ,阳性率为 6 5 .0 % ,其中 +2 0 .0 % , 2 3.3% , 2 1.7% ;PTEN的表达主要定位于乳腺小叶腺泡上皮细胞及导管上皮细胞的胞质 , 4 3.3% ,+36 .7% ,- 2 0 .0 %。 (2 ) c- erb B- 2的表达与淋巴结转移、组织学分级正相关 (P<0 .0 5 ,P<0 .0 1) ,与 ER表达呈负相关 (P<0 .0 1)。PTEN的表达与组织学分级及淋巴结状况呈负相关 (P<0 .0 5 )。 (3)单因素分析显示 c- erb B- 2和 PTEN的表达是预后相关因素 ,c- erb B- 2表达与总生存、无瘤生存相关 (P<0 .0 5 ) ,PTEN与总生存相关 (P<0 .0 5 )。 (4 ) c- erb B- 2表达与 PTEN的表达无显著相关 (P>0 .0 5 ) ,同时存在 c- erb B- 2过表达和 PTEN失表达的乳腺癌患者预后更差。结论 :乳腺癌发生发展中存在多种基因变异 ,c- erb B- 2过度表达与 PTEN的失表达共同促进了肿瘤的发生发展 ,联合检测两者在乳腺癌中的表达情况有助于乳腺癌患者的预后判断 ,为进一步的临床治疗提供依据。 Objective:To determine the expressions of c-erbB-2 and PTEN and their relationships with clinicopathologic parameters and prognosis in breast cancer.Methods:60 cases conducted radical or modified radical mastectomy were followed and studied ,paraffin-embedded specimens were detected c-erbB-2 and PTEN expression by using immunohistochemical S-P method.Results:(1)The staining of c-erbB-2 was localized in cellar membrane and the positive rate was 65%(+20%,23.3%,21.7%).the staining of PTEN was localized in cytoplasm of epithelium cells of lobular acini and epithelium cells of ducts.20.0% breast carcinoma tissues were negative of PTEN protein ,36.7% had weak expression of PTEN and 43.3% had strong expression .(2)The expression of c-erbB-2 was related to the status of axillary lymph node or histological grade and inversely correlated with the estrogen receptor (ER) status.There was inverse relation between the expression of PTEN and the status of axillary lymph node or histological grade.(3)A unifactor analysis indicated that c-erbB-2 had a significant prognostic value in both the overall survival (OS) and the disease free survival (DFS). PTEN demonstrated a prognostic significance only for OS.(4) There was no significant association between the expression of c-erbB-2 and PTEN (P>0.05). A unifactor analysis also indicated a subgroup with high c-erbB-2 expression and low PTEN expression have both a worse DFS and OS than the other subgroups.Conclusion:This study suggested that the mutation of gene of c-erbB-2 and PTEN play a pivotal role in the development and metastatic behavior of primary breast carcinoma,therefore adjuvant therapies after surgery were necessary.
出处 《南通医学院学报》 2004年第1期36-38,41,共4页 ACTA Academiae Medicinae Nantong
关键词 乳腺癌 c—erbB-2 PTEN 预后 免疫组织化学 Breast neoplasms c-erbB-2 PTEN Prognosis Immunohistochemistry
  • 相关文献

参考文献10

  • 1项友群,徐美荣,方庆安.腋淋巴结阴性乳癌的雌激素受体、c-erb B-2表达与预后相关分析[J].南通医学院学报,2003,23(1):27-28. 被引量:4
  • 2郭双平,翟宇强,王文亮,马福成.抑癌基因PTEN在乳腺癌中的表达及意义[J].肿瘤,2002,22(4):271-273. 被引量:5
  • 3Reed W,Hannisdal E,Boehler PJ. The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breaset carcinoma[J]. Cancer,2000,88(4) : 804.
  • 4Tsutsui S,Ohno S,Murakami S,et al. Prognostic value of c-erbB-2 expression in breast cancer[J]. J Surg Oncol,2002,79(4) : 216.
  • 5Paik S,Bryant J,Park C,et al. erbB-2 and response to doxorubicin in patients with axillary lymph node positives,hormone receptor negatives breast cancer[J]. J Natl Cancer Inst,1998,90(18) : 1361.
  • 6Dowsett M ,Harper- Wynne C, Boeddinghaus I, et al.HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer[J]. Cancer Res, 2001,61 (23) :8452.
  • 7Vogel CL,Cobleigh MA,Trpathy D,et al. Efficacy and safety of Herceptin (trastuzumab humanized anti-HER2 antibody) as a single agent in first line treatment of HER2 overexpressing metastatic breast cancer(HER2+/MBC)[J]. Breast Cancer Res Treat, 1998,50 : 23A.
  • 8Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers[J]. Nat Genet,1997.15 : 356.
  • 9Li J,Yen C,Liaw D,et al. PTEN,a putative protein tyrosine phosphatase gene mutated in human brain,breast, and prostate cancer [J]. Science, 1997, 275 :1943.
  • 10Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast[J]. Am J Pathol,1999,155(4) : 1253.

二级参考文献16

  • 1[1]LiJ, YenC, LiawD, etal. PTEN, aputative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate esncer[J]. Science, 1997, 275:1943
  • 2[2]Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor B[J]. Cancer Res, 1997, 57:2124
  • 3[3]Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers[J]. Nat Genet, 1997, 15:356
  • 4[4]Kerr RA. A surprising function for the PTEN tumor suppressor [J]. Science, 1998,282;1027
  • 5[5]Cantley LC, Neel BG. New insights into tumor suppression:PTEN suppress tumor formation by restraining the phospho-inositide 3-kinase/Akt pathway[J]. Pro Natl Sci USA, 1999,96: 4240
  • 6[6]Hampel H, Peltomaki P. Hereditary colorectal cancer: risk assessment and management[J]. Clin Genet, 2000, 58(2): 89
  • 7[7]Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome[J]. Nat Genet, 1997, 16:64
  • 8[8]Eng C, Peacocke M. PTEN and inherited hamartoma-cancer syndromes[J]. Nat Genet, 1998, 19:223
  • 9[9]Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinorma[J]. Cancer Res,1998, 58:3254
  • 10[10]Maxwell GL, Risinger JL, Gumbs C, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasia [J].Cancer Res, 1998, 58:2500

共引文献7

同被引文献30

  • 1[30]Braun S, Pantel K. Micrometastatic bone marrow involvement:detection and prognostic significance [ J]. Med Oncol, 1999, 16(3): 154-165.
  • 2[31]Fehm T, Becker S, Pergola G, et al. Influence of tumor biological factors on tumor cell dissemination in primary breast cancer[J]. Anticancer Res,2004,24(6) :4211-4216.
  • 3[1]Harris AL, Nicholson S, Sainsbury R. Epidermal growth factor receptor and other oncogenes as prognostic markers [ J ]. J Natl Cancer Inst Monogr, 1992, (11 ): 181-187.
  • 4[2]Slamon OJ, Clsrk GM, Wang SG, et al. Human breast cancer:correlation of relapse and survival with amplification of the Her-2/neu oncogene [ J ]. Science, 1987,235:177.
  • 5[3]Ciocca DR, Fujimura FK, Tandon AK, et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers[J]. J Natl Cancer Inst, 1992,84(16): 1279-1282.
  • 6[4]Kato T, Kameoka S, Kimura T, et al. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer[J].Anticancer Res, 2002,22 (2B): 1097-1103.
  • 7[5]Burcombe R J, Makris A, Richman PI, et al. Evaluation of ER,PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer[ J]. Br J Cancer, 2005,92( 1 ): 147-155.
  • 8[6]DiGiovanna MP, Stern DF, Edgerton SM, et al, Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients[ J ]. J Clin Oncol, 2005,23(6): 1152-1160.
  • 9[7]Roos G, Nilsson P, Cajander S, et al. Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer[ J]. Int J Cancer, 1998,79(4): 343-348.
  • 10[8]Yamashita H, Nishio M, Toyama T, et al. Coexistence of HER2over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer[J]. Breast Cancer Res,2004,6(1): R24-130.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部